About Ratio Therapeutics
Ratio Therapeutics is a private company based in Boston, Massachusetts. It has reported $120,674,974 raised in two offerings on Form D since December 2023. Its chief executive is John Hoppin.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 16, 2026 | Jul 31, 2026 | $69,999,974fully sold | 57 | $1.2M | EquityRule 506(b) | Form D ↗ |
| Dec 7, 2023 | Dec 21, 2023 | $50,675,000fully sold | 46 | $1.1M | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $120,674,974 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Ratio Therapeutics's Form D filed Jul 31, 2026.
Earlier filings also listed Shawn Hillier (executive officer, last listed Dec 2023), Scott Holbrook (director, last listed Dec 2023), Reed Malleck (executive officer, last listed Dec 2023), Matthias Friebe (executive officer, last listed Dec 2023), John Garvey (executive officer, last listed Dec 2023) and Jacob Hesterman (executive officer, last listed Dec 2023).